-
D154298-5g
3,5-Dimethyl-4-nitroisoxazole (C007B-118220)
Price: $103.67List Price: $115.193,5-Dimethyl-4-nitroisoxazole was used in the synthesis of: · series of methylene bis-isoxazolo[4,5-b]azepines, via reaction with methylene bis-chalcones · phenylmethylene bis-isoxazolo[4,5-b]azepine derivatives · 3-arylglutaric acids, -
L080200-04
4 5-DICYANOIMIDAZOLE ACTIVATOR 0.25M IN ACETONITRILE
Price: $2,913.09List Price: $3,236.764 5-DICYANOIMIDAZOLE ACTIVATOR 0.25M IN ACETONITRILE -
L380045-06
4 5-DICYANOIMIDAZOLE ACTIVATOR 0.25M IN ACETONITRILE (C005B-466901)
Price: $1,277.96List Price: $1,419.96DCI Activator -
R804800-1EA
4-(2-(4-NITROBENZOYL)CARBOHYDRAZONOYL)PH ENYL 2-FLUOROBENZOATE - 10MG
Price: $91.69List Price: $101.88Other Notes Please note that Sigma-Aldrich provides this product to early discovery researchers as part of a collection of rare and unique chemicals. Sigma-Aldrich does not collect analytical data for this product. -
B2311-5MG
5-(2-BENZOTHIAZOLYL)-3-ETHYL-2-[2-(METHYLPHENYLAMINO)ETHENYL]-1-PHENYL-1H-BENZIMIDAZOLIUM IODIDE >=98% HPLC
Price: $407.64List Price: $452.94Biochem/physiol Actions 5-(2-Benzothiazolyl)-3-ethyl-2-[2-(methylphenylamino)-ethenyl]-1-phenyl-1H-benzimidazolium, or Akt Inhibitor IV, is a cell-permeable benzimidazole compound that inhibits Akt phosphorylation/activation by targeting the ATP -
-
366978-5G
5-FLUOROISATIN 97%
Price: $134.57List Price: $149.535-Fluoroisatin has been reported as the precursor of the Sunitinib (Sutent) drug. 5-Fluoroisatin has been approved by the Food and Drugs Administration (FDA) in 2006 for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor -
F138845-100g
5-Fluoroisatin (C007B-160868)
Price: $460.01List Price: $511.125-Fluoroisatin has been reported as the precursor of the Sunitinib (Sutent) drug. 5-Fluoroisatin has been approved by the Food and Drugs Administration (FDA) in 2006 for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor -
F138845-10g
5-Fluoroisatin (C007B-160869)
Price: $107.13List Price: $119.045-Fluoroisatin has been reported as the precursor of the Sunitinib (Sutent) drug. 5-Fluoroisatin has been approved by the Food and Drugs Administration (FDA) in 2006 for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor -
F138845-25g
5-Fluoroisatin (C007B-160870)
Price: $171.17List Price: $190.195-Fluoroisatin has been reported as the precursor of the Sunitinib (Sutent) drug. 5-Fluoroisatin has been approved by the Food and Drugs Administration (FDA) in 2006 for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor -
F138845-500g
5-Fluoroisatin (C007B-160871)
Price: $1,871.18List Price: $2,079.095-Fluoroisatin has been reported as the precursor of the Sunitinib (Sutent) drug. 5-Fluoroisatin has been approved by the Food and Drugs Administration (FDA) in 2006 for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor -
F138845-5g
5-Fluoroisatin (C007B-160872)
Price: $69.80List Price: $77.565-Fluoroisatin has been reported as the precursor of the Sunitinib (Sutent) drug. 5-Fluoroisatin has been approved by the Food and Drugs Administration (FDA) in 2006 for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor